Hemophilia A

The FDA approved marstacimab-hncq for treatment of certain individuals with hemophilia.

Giroctocogene fitelparvovec reduced bleeding for men with moderately severe to severe hemophilia A, according to data released by the agent’s manufacturer.

Efanesoctocog alfa prophylaxis exhibited high sustained factor VIII activity among younger children with severe hemophilia, according to findings published in The New England Journal of Medicine.

In this video, Lindsey A. George, MD, discussed updated clinical trial data around hemophilia gene therapy presented at ASH Annual Meeting and Exposition.

In this video, Lindsey A. George, MD, talked about improving the function of factor VIII variants for hemophilia A gene therapy, which she presented in a session at ASH Annual Meeting and Exposition.

SAN DIEGO — Efanesoctocog alfa prophylaxis is conventionally cost-ineffective compared with standard factor VIII for patients with severe hemophilia A without inhibitors, according to results presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Emicizumab exhibited efficacy for infants with severe hemophilia A without factor VIII inhibitors, according to study results presented at ASH Annual Meeting and Exposition.

Elderly individuals with moderate or severe hemophilia had poorer joint or functional status and greater joint pain sensitivity than those with mild hemophilia or healthy controls, according to study results.

The FDA announced several regulatory actions.

FDA approved valoctocogene roxaparvovec-rvox for the treatment of certain adults with severe hemophilia A, according to the agent’s manufacturer.